Influence of Schistosoma mansoni infection on faecal calprotectin in the context of HIV, hepatitis B, and malaria co-infections
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The role of gut inflammation for intestinal schistosomiasis remains poorly understood in chronically infected and repeatedly treated populations.
Methods
We conducted a cross-sectional study nested in the SchistoTrack cohort within Pakwach district, Uganda. In 2024, 640 participants aged 6-85 years were examined for Schistosoma mansoni by Kato-Katz. fCal concentration was measured by ELISA. fCal was analysed as binary outcomes (detectable, ≥100 µg/g, >250 µg/g) and natural log-transformed continuous values. Co-endemic infections (malaria, HIV, hepatitis B (HBV)) and diverse sociodemographic covariates were investigated in logistic regressions with covariate selection. Correlations of symptoms, medications, and circulating white blood cells (WBC) with infections and fCal were reported.
Results
74.4% of participants had detectable fCal, 22.3% had fCal ≥100 µg/g, and 7.0% had fCal >250 µg/g. S. mansoni prevalence was 49.1% (median 144 eggs per gram, IQR 36-369). Infection intensity was positively associated with all fCal outcomes (detectable: OR 1.20, ≥100 µg/g: OR 1.11, >250 µg/g: OR 1.26; continuous: β = 0.06) while status was positively related to all but the continuous fCal outcome. HIV was associated with fCal ≥100 µg/g (OR 2.52), while malaria and HBV were uninformative. Spearman analyses revealed significant and weak positive correlations between fCal, WBCs (neutrophils, monocytes and lymphocytes), faecal occult blood, medications (praziquantel and anti-inflammatories) and gastrointestinal symptoms (blood in stool).
Conclusions
S. mansoni infections are characterised by persistent, clinically concerning levels of gut inflammation in chronically infected populations with repeated praziquantel treatment. Integration of fCal thresholds into clinical guidelines may improve management of schistosomiasis-related morbidity.
